India’s Top Deck Backs Patent Box Policies, Four-Prong Strategy
Generics For Growth, Innovation For Future
Executive Summary
C-suite executives from Sun Pharma, Zydus, Dr Reddy’s, Biocon, Piramal and Bharat Serums discuss future growth drivers as the generics opportunity shrinks. Favorable patent box policies, open-source innovation and areas like gene therapy and orphan diseases feature among ideas thrown up.
You may also be interested in...
Takeda-BIRAC Alliance Deepens Big Pharma Support For Biotech Start-ups In India
Takeda’s alliance with BIRAC marks a deepening of big pharma’s support for India’s budding biotech innovation ecosystem. Takeda brings strengths in rare diseases and immunology to a table shared by others like Pfizer and Novartis. Meanwhile, the proposed National Pharmaceutical Policy is seen furthering innovation via public-private partnerships
Asia Deal Watch: SciClone Obtains Commercial Rights In China To Menarini Breast Cancer Drug
Plus deals involving Fujimoto/Egetis, Chugai/Cheplapharm, Celest/Senti, Shionogi/Apnimed, Jiangsu Hengrui/Merck KGaA, Jiangsu Hengrui/Elevar, Sun/Zydus, C4U/Healiva, Shanghai Henlius/Intas, Ono/Turbine, EpimAB/Almirall and Alar/Indivior.
Whiteboarding Ideas From Novartis, Novo To Address India’s Elephants In The Room, ‘On Streets’
Senior VPs from Novartis and Novo Nordisk offered suggestions ranging from protecting IP and fixing the perception of “elephants roaming the streets,” to “fit for purpose” global development plans to improve the research landscape in India, during a recent webinar, which also saw academia weighing in on various issues.